(Q44371559)

2 December 2017

title

Milnacipran in the treatment of bulimia nervosa: a report of 16 cases (English)

1 reference

2 December 2017

1 reference

6

1 reference

2 December 2017

2

Martina de Zwaan

0 references

author name string

Nadia El-Giamal

1

1 reference

2 December 2017

Martina de Zwaan

2

1 reference

2 December 2017

Ursula Bailer

3

1 reference

2 December 2017

Alexandra Strnad

4

1 reference

2 December 2017

Petra Schüssler

5

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

European Neuropsychopharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

13

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

73-79

1 reference

Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Treatment of bulimia with desipramine: a double-blind crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Reboxetine in the treatment of bulimia nervosa: a report of seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Treating bulimia with desipramine. A double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Decreased serotonin function in bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Alterations in serotonin activity and psychiatric symptoms after recovery from bulimia nervosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

CSF monoamine levels in normal-weight bulimia: evidence for abnormal noradrenergic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

New aspects of diagnosis and pharmacotherapy of eating disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Plasma prolactin response to D-fenfluramine is blunted in bulimic patients with frequent binge episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Efficacy and tolerability of milnacipran: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Central and peripheral noradrenalin regulation in eating disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Symptomatic relapse in bulimia nervosa following acute tryptophan depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

[123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Long-term outcome of antidepressant treatment for bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Medication and psychotherapy in the treatment of bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Acute tryptophan depletion in bulimia: effects on large neutral amino acids.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

Serotonin function following remission from bulimia nervosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2802%2900126-8

7 January 2021

10.1016/S0924-977X(02)00126-8

Identifiers

DOI

1 reference

2 December 2017

1 reference